In Vitro Viability and Cytotoxicity Testing and Same-Well Multi-Parametric Combinations for High Throughput Screening

Andrew L. Niles*, Richard A. Moravec, Terry L. Riss
Research Department, Promega Corporation, 2800 Woods Hollow Road, Madison, WI, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1536
Abstract HTML Views: 598
PDF Downloads: 237
Total Views/Downloads: 2371
Unique Statistics:

Full-Text HTML Views: 429
Abstract HTML Views: 290
PDF Downloads: 168
Total Views/Downloads: 887

© Niles et al.; Licensee Bentham Open.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the Research Department, Promega Corporation, 2800 Woods Hollow Road, Madison, WI, USA; E-mail:


In vitro cytotoxicity testing has become an integral aspect of drug discovery because it is a convenient, costeffective, and predictive means of characterizing the toxic potential of new chemical entities. The early and routine implementation of this testing is testament to its prognostic importance for humans. Although a plethora of assay chemistries and methods exist for 96-well formats, few are practical and sufficiently sensitive enough for application in high throughput screening (HTS). Here we briefly describe a handful of the currently most robust and validated HTS assays for accurate and efficient assessment of cytotoxic risk. We also provide guidance for successful HTS implementation and discuss unique merits and detractions inherent in each method. Lastly, we discuss the advantages of combining specific HTS compatible assays into multi-parametric, same-well formats.